Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Genmab invents and sells antibody medicines for cancer and other serious diseases, and also earns royalties when partners sell drugs it helped create.
Genmab is a Danish biotech company that designs antibody drugs — lab-made proteins that latch onto a specific target in the body and either attack a cancer cell or flag it for the immune system to destroy. Its best-known product is a treatment for a blood cancer called multiple myeloma, sold in partnership with Johnson & Johnson, and a second multiple myeloma drug it sells largely through a partner as well. It also has medicines for head and neck cancer and cervical cancer, plus a pipeline of experimental drugs in earlier stages.
The money comes from a few places. Genmab books sales of its own approved drugs when it sells them itself, collects royalties when a partner sells a drug the two companies developed together, and takes a share of profit on partnered products. It also earns milestone payments — lump sums paid when a drug hits a research or regulatory goal. This mix matters: royalty and profit-share income arrives with almost no added cost, so a single successful partnered drug can throw off cash for years. The catch is that Genmab is heavily dependent on a small number of big products and partners. Its multiple myeloma franchise, largely driven by the Johnson & Johnson partnership, has been the engine of its growth, and competition from newer treatments — including rival drugs from Pfizer and Bristol Myers Squibb — is a real threat. Genmab has responded by building out its own commercial operation and buying rights to a rival's drug, spending real money to become less of a pure licenser and more of a company that sells its own medicines. Genmab is profitable and generates solid free cash flow, which it has used to fund research, buy back shares, and strike deals rather than pay a big dividend. It is a company whose fortunes rest on the science: a trial that succeeds can be worth billions, and one that fails can erase years of hope. The simple version is that Genmab sells the recipe and often lets bigger partners do the cooking — and the royalty checks are the whole point.
Saved answer · last researched 23 Oct 2026
see a list of the most recent 300 searches below: